Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 (anti-HER3 mAb) in combination with Cetuximab (anti-EGFR mAb) in sqNSCLC

Under this collaboration, Hummingbird Bioscience will evaluate the safety, tolerability, and anti-tumor activity of HMBD-001 + Cetuximab and Merck will supply Cetuximab to evaluate this combination

Phase 1b clinical trial will be initiated in the H2 2023

“We are excited to collaborate with Merck to study a promising, new treatment regimen for sqNSCLC patients with significant unmet needs. This is the first squamous disease setting of several for which HER3 plays a critical role in etiology and where HER targeted therapies could potentially deliver clinical benefit,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience